Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its lipid nanoparticle tech into the clinic. The Massachusetts-based company has ...

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Jeito claimed the new bankroll, which will support 15 to 20 clinical-stage companies, is the largest ever for a “fully ...